• Black Twitter Icon
  • Black LinkedIn Icon

February 17, 2017

This week the fight against Alzheimer’s disease received another setback when Merck halted the Phase 2/3 trial for their beta-site amyloid precursor protein cleaving enzyme (BACE) inhibitor, verubecestat, in patients with mild-to-moderate Alzheimer’s disease. The decis...

Please reload

THE MEDUCOM POST

Please reload

Please reload

Archives

November 14, 2019

October 29, 2019

Please reload

Recent Posts